Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker EWTX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) NCT07795814 · Heart Failure With Preserved Ejection Fraction EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg | EWTX Edgewise Therapeutics, Inc. | Phase 2 | Recruiting | 90 | Dec 2027 | Registry ↗ |
| Sep 21, 2026 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) NCT05291091 · Becker Muscular Dystrophy Sevasemten 10 mg, Sevasemten 5 mg | EWTX Edgewise Therapeutics, Inc. | Phase 2 | Completed | 244 | Sep 7, 2026 | Registry ↗ |
| Sep 17, 2026 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy NCT06066580 · Becker Muscular Dystrophy Sevasemten | EWTX Edgewise Therapeutics, Inc. | Phase 2 | Enrolling by invitation | 260 | Feb 2031 | Registry ↗ |
| Aug 5, 2026 | A Study of EDG-15400 in Healthy Adults NCT07177066 · Healthy Adults EDG-15400, Placebo | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 84 | Apr 29, 2026 | Registry ↗ |
| Jul 31, 2026 | A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults NCT07456059 · Healthy Adult Participants EDG-7500 | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 24 | Jun 1, 2026 | Registry ↗ |
| Jul 31, 2026 | A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment NCT07324616 · Hepatic Impairment (HI) EDG-7500 | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 25 | Apr 7, 2026 | Registry ↗ |
| Jul 31, 2026 | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) NCT06347159 · Hypertrophic Cardiomyopathy EDG-7500, EDG-7500 | EWTX Edgewise Therapeutics, Inc. | Phase 2 | Active, not recruiting | 79 | Dec 2027 | Registry ↗ |
| Mar 12, 2026 | A Study to Evaluate EDG-7500 in People With Renal Impairment NCT07034768 · Renal Impairments EDG-7500 | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 37 | Dec 22, 2025 | Registry ↗ |
| Nov 12, 2025 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) NCT05540860 · Duchenne Muscular Dystrophy Sevasemten Dose 1, Sevasemten Dose 2 | EWTX Edgewise Therapeutics, Inc. | Phase 2 | Active, not recruiting | 76 | Jan 2027 | Registry ↗ |
| Nov 6, 2025 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously T… NCT06100887 · Duchenne Muscular Dystrophy Sevasemten Dose 1, Sevasemten Dose 2 | EWTX Edgewise Therapeutics, Inc. | Phase 2 | Active, not recruiting | 43 | Mar 2027 | Registry ↗ |
| Jun 24, 2025 | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy NCT05160415 · Becker Muscular Dystrophy Sevasemten | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 12 | Mar 1, 2024 | Registry ↗ |
| Apr 16, 2025 | A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 NCT06738836 · Healthy Volunteer [14C]-EDG-7500 | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 8 | Jan 17, 2025 | Registry ↗ |
| Apr 8, 2025 | A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers NCT06916897 · Healthy Subjects sevasemten, Verapamil | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 42 | Feb 22, 2025 | Registry ↗ |
| Jul 16, 2024 | A Study of EDG-7500 in Healthy Adults NCT06011317 · Healthy Subjects EDG-7500, Placebo | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 84 | May 23, 2024 | Registry ↗ |
| Apr 18, 2023 | Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers NCT05730842 · Healthy Volunteer, Muscular Dystrophies EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 15 | Apr 6, 2023 | Registry ↗ |
| Sep 2, 2022 | A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling NCT05492734 · Muscular Dystrophies EDG-5506 | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 10 | Aug 19, 2022 | Registry ↗ |
| Jun 28, 2022 | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscula… NCT04585464 · Healthy Volunteer, Becker Muscular Dystrophy EDG-5506, Placebo | EWTX Edgewise Therapeutics, Inc. | Phase 1 | Completed | 127 | Nov 15, 2021 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:13 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances